Media headlines about Horizon Pharma PLC (NASDAQ:HZNP) have trended somewhat positive this week, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Horizon Pharma PLC earned a news impact score of 0.24 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.4472532252433 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Horizon Pharma weighs sale of primary care unit -sources – Reuters (reuters.com)
- Horizon Pharma mulling sale of primary care drugs unit; shares ease 2% (seekingalpha.com)
- Short Interest in Horizon Pharma PLC (HZNP) Declines By 6.6% (americanbankingnews.com)
- Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : September 14, 2017 (finance.yahoo.com)
- Horizon Pharma : Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (4-traders.com)
HZNP has been the topic of several recent research reports. UBS AG set a $16.00 price objective on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Piper Jaffray Companies set a $18.00 target price on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Monday, August 7th. BidaskClub upgraded shares of Horizon Pharma PLC from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Cantor Fitzgerald set a $13.00 target price on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Monday, July 31st. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $17.00 target price on shares of Horizon Pharma PLC in a report on Friday, July 28th. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $18.67.
Horizon Pharma PLC (NASDAQ:HZNP) traded down 1.46% during mid-day trading on Friday, hitting $12.11. 7,899,141 shares of the company traded hands. The company’s 50-day moving average price is $12.81 and its 200 day moving average price is $13.04. The company’s market capitalization is $1.98 billion. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $21.98.
Horizon Pharma PLC (NASDAQ:HZNP) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.29. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The business had revenue of $289.51 million during the quarter, compared to analysts’ expectations of $237.01 million. During the same period in the prior year, the business earned $0.56 EPS. Horizon Pharma PLC’s revenue for the quarter was up 12.5% compared to the same quarter last year. On average, analysts anticipate that Horizon Pharma PLC will post $1.08 earnings per share for the current fiscal year.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.